GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Cash Receipts from Fees and Commissions

Immutep (ASX:IMM) Cash Receipts from Fees and Commissions


View and export this data going back to 1988. Start your Free Trial

What is Immutep Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applies to banks.


Immutep (ASX:IMM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Cash Receipts from Fees and Commissions
Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.